Beijing COSCI-REMD Biotherapeutics Co., Ltd.

Primary objectives: 1) To evaluate the safety and tolerability of a single subcutaneous injection of Volagidemab in healthy Chinese adult subjects. Secondary objectives: 1) To evaluate the pharmacokinetic (PK) characteristics and pharmacodynamics (PD) of Volagidemab in healthy Chinese adult subjects after a single subcutaneous injection. 2) To explore the effect of a single subcutaneous injection of Volagidemab on liver function in healthy Chinese adult subjects. 3) To evaluate the immunogenicity of Volagidemab in healthy Chinese adult subjects after a single subcutaneous injection.